01 eTMF

The trial master file, finally maintained.

Built around the DIA TMF Reference Model v3.3.1 with quality checks at upload, not at lock. The workflows match how clinical-ops teams actually work: drag-drop, draft-and-finalise, redact, version, sign.

  • Inspection-ready exports — generate the auditor's bundle in minutes
  • Placeholder generation for required artefacts that haven't arrived yet
  • Cross-reference checks against protocol version, country pack, site pack
  • Read-only auditor portal with scoped, time-bounded access
📁
Country Pack — Germany
97% complete · 4 placeholders
📁
Sponsor Pack
100% complete
📁
Site Pack — SITE-009 · Berlin
4 placeholders open
📁
Site Pack — SITE-027 · Toronto
100% complete
02 Site activation

Every regulatory milestone, in one queue.

Replace the activation tracker, the SharePoint folder, and the email thread with a single workspace where every team — sponsor, CRO, vendor, site — sees what's next and who owns it.

  • Pre-built workflows for FDA IND, EMA CTA, MHRA, Health Canada
  • Country checklists kept current by our regulatory team
  • Contract redlines and execution tracked against the trial budget
  • Activation-cycle benchmarking against our anonymised customer cohort
Reg. submission
SITE-009 · IRB pending
SITE-021 · CTA review
Contracts
SITE-014 · countersign
SITE-024 · redlines
SITE-031 · drafted
Active
SITE-027
SITE-018
SITE-006
SITE-002
03 Monitoring & RBQM

Risk dashboards that point at the next call.

Define the protocol's critical-to-quality factors once. Monitor them across every site, with triggers that fire on drift — not after the fact. Visit reports, action items, and source documents share the same workspace.

  • Centralised statistical monitoring backed by your CtQ factors
  • Visit scheduling that adjusts to risk profile, not just calendar cadence
  • Standard and custom triggers — adverse-event cadence, withdrawal rate, SDV variance
  • Auditable record of every risk decision and who made it
SDV variance — SITE-014
+1.8σ from cohort baseline
trigger
Visit overdue · SITE-024
38 days, target 30
trigger
AE reporting cadence — normal
SITE-027
✓ ok
Withdrawal rate — within tolerance
Cohort B
✓ ok
04 Regulatory submissions

eCTD-aware, signed, and ready to file.

Document organisation that mirrors how regulators expect the dossier. Electronic signatures with long-term validation. Health-authority correspondence linked to the artefacts it references.

  • eCTD-compliant document organisation and metadata
  • Advanced electronic signatures, eIDAS-conformant
  • Submission tracker with health-authority correspondence
  • Side-by-side version compare for amendment cycles
📜
Module 2.5 — Clinical overview
v3.0 · LTA timestamp valid
📜
Module 5.3.5.1 — Study report
v1.2 · final
📜
FDA correspondence — IND amendment
2026-03-08 · awaiting response
○ open
📜
EMA correspondence — Day 90
Response received 2026-04-22

Compliance & validation

Designed and validated to support GxP-regulated clinical trials worldwide:

Validation packages, IQ/OQ/PQ documentation, and our Quality Manual are available under NDA to qualified prospects and customers. Infrastructure runs in AWS regions you choose: us-east-1, eu-west-1, or eu-central-1.

Pricing

Per study, per module, with portfolio discounts for sponsors and CROs running multiple programs. We don't publish a price list because no two clinical programs look the same. Talk to us about your protocol and we'll quote in writing within a week.

Implementation

Most customers go live in 4–8 weeks for a single study. Larger CRO rollouts typically take 12–16 weeks including SOP alignment and validation. Every implementation includes a named clinical-operations consultant from our team — not a project manager.

Request a demo